Palvella Therapeutics, Inc. (PVLA)
| Market Cap | 2.19B +407.8% |
| Revenue (ttm) | n/a |
| Net Income | -61.70M |
| EPS | -4.90 |
| Shares Out | 14.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,007 |
| Open | 156.07 |
| Previous Close | 157.77 |
| Day's Range | 151.89 - 157.96 |
| 52-Week Range | 40.22 - 161.38 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 230.53 (+51.45%) |
| Earnings Date | Aug 4, 2026 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for PVLA stock is "Strong Buy." The 12-month stock price target is $230.53, which is an increase of 51.45% from the latest price.
News
Palvella Therapeutics price target lowered to $207 from $210 at Truist
Truist lowered the firm’s price target on Palvella Therapeutics (PVLA) to $207 from $210 and keeps a Buy rating on the shares.
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializi...
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $232 from $227 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Palvella Therapeutics reports Q2 EPS ($1.52), consensus ($1.15)
“We made significant progress during the second quarter, completing our pre-NDA meeting with FDA and initiating the rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations,”...
Palvella Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw major milestones, including positive phase III results for QTORIN rapamycin in mLM, rolling NDA submission, and a $230M capital raise. The company is well-funded for launch and pipeline expansion, with multiple rare disease programs advancing and strong physician and payer interest.
Palvella Therapeutics Earnings release: Q2 2026
Palvella Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Palvella Therapeutics Quarterly report: Q2 2026
Palvella Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Palvella Therapeutics Slides: Q2 2026
Palvella Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for...
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising FDA-approved drugs for repurposing, with the potential to accelerate patient access to effective the...
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializ...
H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial
H.C. Wainwright notes that on Monday, Palvella Therapeutics (PVLA) closed down 21% compared to the previous weeks close, which the firm believes was an overreaction to the updated corporate deck…
Palvella Therapeutics selloff a buying opportunity, says BTIG
Palvella shares fell sharply after the FDA declined to grant Breakthrough Therapy Designation for QTORIN in cVMs, but the decision does not change the program’s strong clinical data, regulatory path,…
Palvella Therapeutics falls -13.6%
Palvella Therapeutics (PVLA) is down -13.6%, or -$21.36 to $135.88.
Palvella Therapeutics falls -9.0%
Palvella Therapeutics (PVLA) is down -9.0%, or -$14.11 to $143.13.
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
Palvella Therapeutics (PVLA) announced the appointment of Matt Pauls to its board of directors. Since 2020, he has served as chair of the board of directors and CEO of Savara…
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options
Palvella submits first rolling new drug application to FDA for Qtorin
Palvella Therapeutics (PVLA) announced that the company has submitted the first module of its rolling new drug application, or NDA, to the FDA seeking approval of Qtorin 3.9% rapamycin anhydrous…
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
Palvella Therapeutics (PVLA) announced today that FDA has granted rolling review for the company’s new drug application, or NDA, for Qtorin rapamycin for the treatment of microcystic lymphatic malform...
FDA Grants Rolling Review of Palvella's QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted
Palvella Therapeutics Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and an equity plan amendment, all of which were approved by majority vote. No questions were submitted by stakeholders during the Q&A session.
Palvella Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing its QTORIN platform for rare skin diseases, highlighted by positive phase III results for QTORIN rapamycin in microcystic lymphatic malformations and a robust pipeline expansion. With $260 million in cash, experienced commercial leadership, and multiple upcoming clinical milestones, it is positioned for significant growth in multi-billion dollar orphan markets.
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
Palvella Therapeutics (PVLA) announced completion of its pre-new drug application meeting with FDA for Qtorin 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations. The pre-NDA meeting a...
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleed...